Physician profile
Dipa Puwar
NPI 1194353086
$3,029.72
in general payments reported to CMS, 2019-2025
15 companies · $1,175 in 2025
The $1,175 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $100 · 2022: $17.04 · 2023: $993 · 2024: $745 · 2025: $1,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,832.54 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,995.30 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $192.79 | 2024-2025 | Tremfya, Stelara |
| Apollo Endosurgery US INC | $155.57 | 2023 | Overstitch Endoscopic Suturing System |
| Janssen Biotech, INC. | $131.98 | 2024-2025 | Stelara, Tremfya |
| Gilead Sciences, INC. | $121.10 | 2023 | Biktarvy |
| Viiv Healthcare Company | $100.15 | 2021 | |
| Novo Nordisk INC | $91.66 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $91.47 | 2025 | Terlivaz |
| Takeda Pharmaceuticals U.S.A., INC. | $40.25 | 2023-2025 | Entyvio, Gattex |
| Regeneron Healthcare Solutions, INC. | $25.02 | 2025 | Dupixent |
| Madrigal Pharmaceuticals | $23.78 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $17.04 | 2022 | |
| Dexcom, INC. | $15.49 | 2023 | Dexcom G6 Transmitter |
| Pfizer INC. | $14.72 | 2025 | |
| Boston Scientific Corporation | $13.40 | 2024 | Hydratome Rx 44 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dipa Puwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.